Docetaxel-cyclosporine A co-encapsulated self-emulsifying preparation and preparation method thereof

A docetaxel, self-emulsifying technology, applied in pharmaceutical formulations, emulsion delivery, non-active components of polymer compounds, etc. to improve bioavailability, improve dissolution, and improve tolerance

Active Publication Date: 2021-03-19
KUNMING JIDA PHARMA
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to solve the shortcomings of the existing docetaxel preparations that only have injections, cannot meet the oral administration of docetaxel, poor patient compliance, and need to be pretreated with hormones before administration, researchers have carried out a lot of research, aiming to improve the multi- Oral bioavailability of docetaxel, but the effect is minimal. The oral bioavailability of docetaxel reported so far is low, which cannot meet the oral needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Docetaxel-cyclosporine A co-encapsulated self-emulsifying preparation and preparation method thereof
  • Docetaxel-cyclosporine A co-encapsulated self-emulsifying preparation and preparation method thereof
  • Docetaxel-cyclosporine A co-encapsulated self-emulsifying preparation and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] prescription:

[0079] DTX 1g CsA 0.5g MCT 31g ELP 49g IMW 742 7g Absolute ethanol 11.5g total prescription 100g

[0080] Weigh docetaxel and cyclosporine A according to the above prescription, dissolve them completely with absolute ethanol, then add medium-chain triglycerides, polyoxyethylene 35 castor oil, caprylic capric acid mono-diglyceride, Stir well, dispense and seal with a gland.

[0081] The oral bioavailability of docetaxel of the obtained preparation was measured by the method described in the above test example 2, and the result was 52.5%.

Embodiment 2~8

[0083] Using the same method as in Example 1, the preparations of Examples 2 to 8 were prepared according to the prescriptions in Table 9, and the oral bioavailability of docetaxel was determined, as shown in Table 9.

[0084] Table 9

[0085]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to a docetaxel-cyclosporin A co-encapsulated self-emulsifying preparation. The docetaxel-cyclosporin A co-encapsulated self-emulsifying preparation comprises docetaxel, cyclosporin A, an oil phase and an emulsifying agent; the docetaxel and the cyclosporin A are in the weight ratio of 2 to 1. The docetaxel-cyclosporin A co-encapsulated self-emulsifying preparation is a self-emulsifying drug delivery system; the oral bioavailability of the docetaxel can be greatly improved.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, in particular to a docetaxel-cyclosporin A co-encapsulated self-emulsifying preparation and a preparation method thereof. Background technique [0002] Docetaxel (Docetaxel) is a taxane drug, by promoting the assembly of microtubule dimers into microtubules, while stabilizing microtubules by preventing depolymerization, arresting cells in G2 and M phases, thereby inhibiting Mitosis and proliferation of cancer cells. The pharmacological effect of docetaxel is stronger than that of paclitaxel, its intracellular concentration is 3 times higher than that of paclitaxel, and its intracellular residence time is longer, and its affinity for microtubules is 2 times that of paclitaxel; in vitro antitumor activity test, it has been confirmed The antitumor activity of docetaxel is 1.3 to 12 times that of paclitaxel. Clinical studies have shown that for anthracycline-resistant breast cancer, docet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/107A61K31/337A61K47/42A61K47/14A61K47/44A61P35/00
CPCA61K9/0053A61K9/107A61K9/1075A61K31/337A61K47/14A61K47/42A61K47/44A61P35/00
Inventor 程晓波陈成军李英吴梅金寅张云王立江
Owner KUNMING JIDA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products